Balchem Posts Record 2025 Results as Nutrition Segments Drive Growth
Balchem Corporation delivered a 9.8% revenue surge to $263.6M in Q4, with net earnings climbing 16.8% to $39.2M. The Human Nutrition segment led with $166.1M in sales, while Animal Nutrition and Specialty Products showed resilient demand. Full-year EBITDA reached $274.9M despite inflationary pressures.
Gross margins held steady as operational efficiencies offset higher input costs. The company maintains a conservative 0.3x leverage ratio while raising dividends, signaling confidence in its 2026 pipeline. Market reaction remained muted with shares closing at $175.00, down 1.41%.